Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Drugs and Chemicals›Picrotoxin
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Picrotoxin

Drugs and Chemicals · NLM MeSH · updated 2026-10-31 · version 1

Citations verified against PubMedNot yet clinician-reviewed8 referencesApproximately 5 min read

A mixture of picrotoxinin and picrotin that is a noncompetitive antagonist at gaba-a receptors acting as a convulsant.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (942 words), 8 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A mixture of picrotoxinin and picrotin that is a noncompetitive antagonist at gaba-a receptors acting as a convulsant. Picrotoxin blocks the gamma-aminobutyric acid-activated chloride ionophore. Although it is most often used as a research tool, it has been used as a CNS stimulant and an antidote in poisoning by CNS depressants, especially the barbiturates.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Cocculin; 3,6-Methano-8H-1,5,7-trioxacyclopenta(ij)cycloprop(a)azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, (1aR-(1aalpha,2abeta,3beta,6beta,6abeta,8aS*,8bbeta,9S*))-, compd. with (1aR-(1aalpha,2abeta,3beta,6beta,6abeta,8.

Where it fits in the MeSH classification

Broader topics
Cyclohexanes; Sesquiterpenes; Lactones; Plant Extracts; Toxins, Biological

Related concepts

  • Picrotoxinin
  • Picrotin
  • Gaba-A
  • Gamma-Aminobutyric Acid-

Research landscape

PubMed indexes 4,180 records tagged with the MeSH heading “Picrotoxin” (counts retrieved 2026-10-31). 90 of them (2.2%) were published from 2020 onward, and the busiest period so far is through 1999 with 2,817 records.

Reviews account for 68 records (1.6%) and meta-analyses for 1. Randomized controlled trials number 2 (0.0%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 2,817 records; 2000-2009: 841 records; 2010-2019: 432 records; 2020 onward: 90 records2,817through 19998412000-20094322010-2019902020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19992,817
2000-2009841
2010-2019432
2020 onward90
Share of records by publication typeReviews: 1.6 percent; Meta-analyses: 0.0 percent; Randomized controlled trials: 0.0 percentReviews1.6% (68)Meta-analyses0.0% (1)Randomized controlled trials0.0% (2)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 4,180 PubMed records
TypeRecordsShare
Reviews681.6%
Meta-analyses10.0%
Randomized controlled trials20.0%

Method: PubMed query "Picrotoxin"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.

Reading the evidence in drugs and chemicals

Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin
Yoshiike Y, Kimura T, Yamashita S, Furudate H, Mizoroki T, Murayama M, et al.
2008Research article
Design not recorded in structured metadata
89cc by
PMID 18716656 · DOI · PMC2515633
Administration of the GABAA receptor antagonist picrotoxin into rat supramammillary nucleus induces c-Fos in reward-related brain structures. Supramammillary picrotoxin and c-Fos expression
Shin R, Ikemoto S
2010Research article
Design not recorded in structured metadata
23cc by
PMID 20716371 · DOI · PMC2930627
Ginkgolide B and bilobalide block the pore of the 5-HT₃receptor at a location that overlaps the picrotoxin binding site
Thompson AJ, Jarvis GE, Duke RK, Johnston GA, Lummis SC
2011Research article
Design not recorded in structured metadata
21cc by
PMID 21059362 · DOI · PMC3070799
Pharmacological stimulation of infralimbic cortex after fear conditioning facilitates subsequent fear extinction
Bayer H, Hassell JE, Oleksiak CR, Garcia GM, Vaughan HL, Juliano VAL, et al.
2024Research article
Design not recorded in structured metadata
17cc by
PMID 39138373 · DOI · PMC11480363

GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin [1]

Research article Yoshiike Y, Kimura T, Yamashita S, Furudate H, Mizoroki T, Murayama M, et al. · · 2008 · cited 89 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Advanced age and mutations in the genes encoding amyloid precursor protein (APP) and presenilin (PS1) are two serious risk factors for Alzheimer's disease (AD).
Closing excerpt
Therefore, reduced LTP linked to enhanced GABA(A) receptor-mediated inhibition may be triggered by aging and may be accelerated by familial AD-linked gene products like Abeta and mutant PS1, leading to cognitive decline that is pharmacologically treatable at least at this stage of disease progression in mice.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (285 words)

Advanced age and mutations in the genes encoding amyloid precursor protein (APP) and presenilin (PS1) are two serious risk factors for Alzheimer's disease (AD). Finding common pathogenic changes originating from these risks may lead to a new therapeutic strategy. We observed a decline in memory performance and reduction in hippocampal long-term potentiation (LTP) in both mature adult (9-15 months) transgenic APP/PS1 mice and old (19-25 months) non-transgenic (nonTg) mice. By contrast, in the presence of bicuculline, a GABA(A) receptor antagonist, LTP in adult APP/PS1 mice and old nonTg mice was larger than that in adult nonTg mice. The increased LTP levels in bicuculline-treated slices suggested that GABA(A) receptor-mediated inhibition in adult APP/PS1 and old nonTg mice was upregulated. Assuming that enhanced inhibition of LTP mediates memory decline in APP/PS1 mice, we rescued memory deficits in adult APP/PS1 mice by treating them with another GABA(A) receptor antagonist, picrotoxin (PTX), at a non-epileptic dose for 10 days. Among the saline vehicle-treated groups, substantially higher levels of synaptic proteins such as GABA(A) receptor alpha1 subunit, PSD95, and NR2B were observed in APP/PS1 mice than in nonTg control mice. This difference was insignificant among PTX-treated groups, suggesting that memory decline in APP/PS1 mice may result from changes in synaptic protein levels through homeostatic mechanisms. Several independent studies reported previously in aged rodents both an increased level of GABA(A) receptor alpha1 subunit and improvement of cognitive functions by long term GABA(A) receptor antagonist treatment. Therefore, reduced LTP linked to enhanced GABA(A) receptor-mediated inhibition may be triggered by aging and may be accelerated by familial AD-linked gene products like Abeta and mutant PS1, leading to cognitive decline that is pharmacologically treatable at least at this stage of disease progression in mice.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 18716656 · DOI · PMC2515633

Administration of the GABAA receptor antagonist picrotoxin into rat supramammillary nucleus induces c-Fos in reward-related brain structures. Supramammillary picrotoxin and c-Fos expression [2]

Research article Shin R, Ikemoto S · · 2010 · cited 23 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundPicrotoxin blocks GABAA receptors, whose activation typically inhibits neuronal firing activity.
Closing excerpt
These regions may be involved in mediating positive motivational effects triggered by intra-SuM picrotoxin.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (229 words)

BackgroundPicrotoxin blocks GABAA receptors, whose activation typically inhibits neuronal firing activity. We recently found that rats learn to selectively self-administer picrotoxin or bicuculline, another GABAA receptor antagonist, into the supramammillary nucleus (SuM), a posterior hypothalamic structure localized anterior to the ventral tegmental area. Other drugs such as nicotine or the excitatory amino acid AMPA are also self-administered into the SuM. The SuM appears to be functionally linked with the mesolimbic dopamine system and is closely connected with other brain structures that are implicated in motivational processes, including the prefrontal cortex, septal area, preoptic area, lateral hypothalamic area and dorsal raphe nucleus. Here, we hypothesized that these brain structures are activated by picrotoxin injections into the SuM.ResultsPicrotoxin administration into the SuM markedly facilitated locomotion and rearing. Further, it increased c-Fos expression in this region, suggesting blockade of tonic inhibition and thus the disinhibition of local neurons. This manipulation also increased c-Fos expression in structures including the ventral tegmental area, medial shell of the nucleus accumbens, medial prefrontal cortex, septal area, preoptic area, lateral hypothalamic area and dorsal raphe nucleus.ConclusionsPicrotoxin administration into the SuM appears to disinhibit local neurons and recruits activation of brain structures associated with motivational processes, including the mesolimbic dopamine system, prefrontal cortex, septal area, preoptic area, lateral hypothalamic area and dorsal raphe nucleus. These regions may be involved in mediating positive motivational effects triggered by intra-SuM picrotoxin.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 20716371 · DOI · PMC2930627

Ginkgolide B and bilobalide block the pore of the 5-HT₃receptor at a location that overlaps the picrotoxin binding site [3]

Research article Thompson AJ, Jarvis GE, Duke RK, Johnston GA, Lummis SC · · 2011 · cited 21 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Extracts from the Ginkgo biloba tree are widely used as herbal medicines, and include bilobalide (BB) and ginkgolides A and B (GA and GB).
Closing excerpt
Thus these compounds have comparable, although less potent, behaviour than at some other Cys-loop receptors, demonstrating their actions are conserved across the family.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (241 words)

Extracts from the Ginkgo biloba tree are widely used as herbal medicines, and include bilobalide (BB) and ginkgolides A and B (GA and GB). Here we examine their effects on human 5-HT(3)A and 5-HT(3)AB receptors, and compare these to the effects of the structurally related compounds picrotin (PTN) and picrotoxinin (PXN), the two components of picrotoxin (PTX), a known channel blocker of 5-HT(3), nACh and GABA(A) receptors. The compounds inhibited 5-HT-induced responses of 5-HT(3) receptors expressed in Xenopus oocytes, with IC(50) values of 470 μM (BB), 730 μM (GB), 470 μM (PTN), 11 μM (PXN) and >1mM (GA) in 5-HT(3)A receptors, and 3.1mM (BB), 3.9 mM (GB), 2.7 mM (PTN), 62 μM (PXN) and >1mM (GA) in 5-HT(3)AB receptors. Radioligand binding on receptors expressed in HEK 293 cells showed none of the compounds displaced the specific 5-HT(3) receptor antagonist [(3)H]granisetron, confirming that they do not act at the agonist binding site. Inhibition by GB at 5-HT(3)A receptors is weakly use-dependent, and recovery is activity dependent, indicating channel block. To further probe their site of action at 5-HT(3)A receptors, BB and GB were applied alone or in combination with PXN, and the results fitted to a mathematical model; the data revealed partially overlapping sites of action. We conclude that BB and GB block the channel of the 5-HT(3)A receptor. Thus these compounds have comparable, although less potent, behaviour than at some other Cys-loop receptors, demonstrating their actions are conserved across the family.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 21059362 · DOI · PMC3070799

Pharmacological stimulation of infralimbic cortex after fear conditioning facilitates subsequent fear extinction [4]

Research article Bayer H, Hassell JE, Oleksiak CR, Garcia GM, Vaughan HL, Juliano VAL, et al. · · 2024 · cited 17 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
The infralimbic (IL) division of the medial prefrontal cortex (mPFC) is a crucial site for the extinction of conditioned fear memories in rodents.
Closing excerpt
Our data suggest that the IL encodes an inhibitory memory during the consolidation of fear conditioning that is necessary for future fear suppression.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (187 words)

The infralimbic (IL) division of the medial prefrontal cortex (mPFC) is a crucial site for the extinction of conditioned fear memories in rodents. Recent work suggests that neuronal plasticity in the IL that occurs during (or soon after) fear conditioning enables subsequent IL-dependent extinction learning. We therefore hypothesized that pharmacological activation of the IL after fear conditioning would promote the extinction of conditioned fear. To test this hypothesis, we characterized the effects of post-conditioning infusions of the GABAA receptor antagonist, picrotoxin, into the IL on the extinction of auditory conditioned freezing in male and female rats. In four experiments, we found that picrotoxin injections performed immediately, 24 h, or 13 days after fear conditioning reduced conditioned freezing to the auditory conditioned stimulus (CS) during both extinction training and extinction retrieval; this effect was observed up to two weeks after picrotoxin infusions. Interestingly, inhibiting protein synthesis inhibition in the IL immediately after fear conditioning prevented the inhibition of freezing by picrotoxin injected 24 h later. Our data suggest that the IL encodes an inhibitory memory during the consolidation of fear conditioning that is necessary for future fear suppression.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 39138373 · DOI · PMC11480363

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Treatment of vertigo with a homeopathic complex remedy compared with usual treatments: a meta-analysis of clinical trials [5]
    Schneider B, Klein P, Weiser M · Arzneimittelforschung · 2005 · cited 11 times (Europe PMC)
  • Research article Tutu toxicity: three case reports of Coriaria arborea ingestion, review of literature and recommendations for management [6]
    Belcher SF, Morton TR · N Z Med J · 2013 · cited 2 times (Europe PMC)
  • Research article [GABA receptor complex and the mechanisms of action of various anticonvulsants (review of the literature)] [7]
    Aksent'ev SB, Levinskiĭ MV · Zh Nevropatol Psikhiatr Im S S Korsakova · 1990 · cited 0 times (Europe PMC)
  • Research article [TREATMENT OF ACUTE BARBITURATE POISONING] [8]
    COPINSCHI G, CORNIL A, THYS O · Acta Clin Belg · 1963 · cited 0 times (Europe PMC)

References

  1. Yoshiike Y, Kimura T, Yamashita S, Furudate H, Mizoroki T, Murayama M, et al.. GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. . 2008. PMID 18716656 · DOI · PMC2515633
  2. Shin R, Ikemoto S. Administration of the GABAA receptor antagonist picrotoxin into rat supramammillary nucleus induces c-Fos in reward-related brain structures. Supramammillary picrotoxin and c-Fos expression. . 2010. PMID 20716371 · DOI · PMC2930627
  3. Thompson AJ, Jarvis GE, Duke RK, Johnston GA, Lummis SC. Ginkgolide B and bilobalide block the pore of the 5-HT₃receptor at a location that overlaps the picrotoxin binding site. . 2011. PMID 21059362 · DOI · PMC3070799
  4. Bayer H, Hassell JE, Oleksiak CR, Garcia GM, Vaughan HL, Juliano VAL, et al.. Pharmacological stimulation of infralimbic cortex after fear conditioning facilitates subsequent fear extinction. . 2024. PMID 39138373 · DOI · PMC11480363
  5. Schneider B, Klein P, Weiser M. Treatment of vertigo with a homeopathic complex remedy compared with usual treatments: a meta-analysis of clinical trials. Arzneimittelforschung. 2005. PMID 15727161 · DOI
  6. Belcher SF, Morton TR. Tutu toxicity: three case reports of Coriaria arborea ingestion, review of literature and recommendations for management. N Z Med J. 2013. PMID 23474518
  7. Aksent'ev SB, Levinskiĭ MV. [GABA receptor complex and the mechanisms of action of various anticonvulsants (review of the literature)]. Zh Nevropatol Psikhiatr Im S S Korsakova. 1990. PMID 2158715
  8. COPINSCHI G, CORNIL A, THYS O. [TREATMENT OF ACUTE BARBITURATE POISONING]. Acta Clin Belg. 1963. PMID 14045895 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-31.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • CamphorDrugs and Chemicals
  • IsoproterenolDrugs and Chemicals
  • EpinephrineDrugs and Chemicals
  • EmodinDrugs and Chemicals
  • IrbesartanDrugs and Chemicals
  • LosartanDrugs and Chemicals

All 546 articles in Drugs and Chemicals →

At a glance

4,180
PubMed records on this heading
2%
published since 2020
68
review articles
2
randomized trials
8
verified references below

Counts come from PubMed on 2026-10-31; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • CamphorDrugs and Chemicals
  • IsoproterenolDrugs and Chemicals
  • EpinephrineDrugs and Chemicals
  • EmodinDrugs and Chemicals
  • IrbesartanDrugs and Chemicals

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support